Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Private Management Group Inc.

Private Management Group Inc. cut its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 12.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,192,989 shares of the company’s stock after selling 162,630 shares during the quarter. Private Management Group Inc. owned approximately 0.10% of Teva Pharmaceutical Industries worth $24,098,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Menora Mivtachim Holdings LTD. increased its stake in Teva Pharmaceutical Industries by 31.9% during the 2nd quarter. Menora Mivtachim Holdings LTD. now owns 38,493,294 shares of the company’s stock worth $645,148,000 after buying an additional 9,303,978 shares in the last quarter. Soundwatch Capital LLC purchased a new position in shares of Teva Pharmaceutical Industries in the second quarter valued at approximately $143,533,000. Maverick Capital Ltd. lifted its position in shares of Teva Pharmaceutical Industries by 14,351.6% in the second quarter. Maverick Capital Ltd. now owns 4,377,690 shares of the company’s stock valued at $73,370,000 after acquiring an additional 4,347,398 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. boosted its stake in shares of Teva Pharmaceutical Industries by 12.9% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock worth $761,455,000 after acquiring an additional 4,306,363 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its stake in shares of Teva Pharmaceutical Industries by 13.6% in the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 32,582,212 shares of the company’s stock worth $658,161,000 after acquiring an additional 3,896,790 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently commented on TEVA shares. Scotiabank increased their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research note on Thursday, January 29th. Barclays lifted their target price on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an “overweight” rating in a research note on Friday, January 30th. JPMorgan Chase & Co. upped their target price on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a report on Tuesday, December 16th. Jefferies Financial Group increased their target price on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Finally, Bank of America raised their price target on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and a consensus price target of $37.67.

Teva Pharmaceutical Industries Stock Performance

Shares of Teva Pharmaceutical Industries stock opened at $28.54 on Friday. The business’s 50 day moving average price is $32.91 and its 200 day moving average price is $26.62. The company has a market cap of $32.81 billion, a price-to-earnings ratio of 23.78, a PEG ratio of 9.81 and a beta of 0.72. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The company had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.36 billion. During the same period in the prior year, the business earned $0.71 EPS. The firm’s quarterly revenue was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, research analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Insider Activity

In other Teva Pharmaceutical Industries news, EVP Eliyahu Sharon Kalif sold 345,810 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $33.64, for a total transaction of $11,633,048.40. Following the transaction, the executive vice president directly owned 57,478 shares of the company’s stock, valued at $1,933,559.92. The trade was a 85.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Roberto Mignone sold 77,400 shares of the business’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $30.24, for a total transaction of $2,340,576.00. Following the completion of the transaction, the director owned 367,600 shares in the company, valued at $11,116,224. The trade was a 17.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 948,499 shares of company stock worth $30,897,071. Insiders own 0.49% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.